Last reviewed · How we verify
Neocitrullamon (amino(diphenylhydantoin) valeric acid)
Neocitrullamon (generic name: amino(diphenylhydantoin) valeric acid) is a drug. It is currently in unknown development for Epilepsy.
Neocitrullamon is thought to work by stabilizing neuronal membranes and reducing excitability.
Neocitrullamon, also known as amino(diphenylhydantoin) valeric acid, is a small molecule modality with unknown drug class and target. It is approved for the treatment of epilepsy, but its commercial status and key safety considerations are currently unknown. Further research is needed to fully understand its pharmacological properties and potential risks. Neocitrullamon's exact mechanism of action is unclear, but it is believed to work by stabilizing neuronal membranes and reducing excitability. Its development and approval status are also unclear.
At a glance
| Generic name | amino(diphenylhydantoin) valeric acid |
|---|---|
| Therapeutic area | Neuroscience |
| Phase | unknown |
Mechanism of action
Imagine your brain cells are like a rowdy crowd - they're always excited and moving around. Neocitrullamon helps calm them down by making it harder for them to get too excited, which can help prevent seizures. This is done by changing the way the cells' membranes work, making it harder for them to fire off signals too quickly.
Approved indications
- Epilepsy
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neocitrullamon CI brief — competitive landscape report
- Neocitrullamon updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Neocitrullamon
What is Neocitrullamon?
How does Neocitrullamon work?
What is Neocitrullamon used for?
What is the generic name of Neocitrullamon?
What development phase is Neocitrullamon in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Epilepsy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing